A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system

Biomaterials

Volumn 34, Issue 32, 2013, Pages 7980-7993

  Zhang, Qianyu ^a   Tang, Jie ^a   Fu, Ling ^a   Ran, Rui ^a   Liu, Yayuan ^a   Yuan, Mingqing ^a   He, Qin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

C26 tumor model; Liposome; Paclitaxel; PH responsive helical cell penetrating peptide; TH

Indexed keywords

CELL-PENETRATING PEPTIDE; INTRACELLULAR TRAFFICKING; LIPOSOMAL DELIVERY SYSTEM; PACLITAXEL; POSITIVELY CHARGED SURFACES; SYSTEMIC ADMINISTRATION; TUMOR MICROENVIRONMENT; TUMOR MODELS;

AMINO ACIDS; CARDIOVASCULAR SYSTEM; CELL MEMBRANES; DRUG DELIVERY; ENZYME ACTIVITY; LIPOSOMES; MAMMALS; MOLECULAR BIOLOGY; PEPTIDES; THORIUM; TUMORS;

CYTOLOGY;

ALPHA HELICAL CELL PENETRATING PEPTIDE; CELL PENETRATING PEPTIDE; CLATHRIN; LIPOSOME; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL SURFACE; CELLS; CIRCULATION; CONTROLLED STUDY; DRUG TUMOR LEVEL; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTON TRANSPORT; TUMOR XENOGRAFT;

MUS;

EID: 84881026474     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.014     Document Type: Article

References (52)

1. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465.
2. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989, 49:4373-4384.
3. Wojtkowiak J.W., Verduzco D., Schramm K.J., Gillies R.J. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 2011, 8:2032-2038.
4. Tian L., Bae Y.H. Cancer nanomedicines targeting tumor extracellular pH. Colloids Surf B Biointerfaces 2012, 99:116-126.
5. Kwon I.K., Lee S.C., Han B., Park K. Analysis on the current status of targeted drug delivery to tumors. JControl Release 2012, 164:108-114.
6. Wang M., Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010, 62:90-99.
7. Elbayoumi T.A., Torchilin V.P. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol Pharm 2009, 6:246-254.
8. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013, 65:36-48.
9. Ezzat K., Zaghloul E.M., El Andaloussi S., Lehto T., El-Sayed R., Magdy T. Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. JControl Release 2012, 162:1-8.
10. Vivès E. Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse to wild to go only to Troy?". JControl Release 2005, 109:77-85.
11. Zhu L., Kate P., Torchilin V.P. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 2012, 6:3491-3498.
12. Kuai R., Yuan W., Qin Y., Chen H., Tang J., Yuan M., et al. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol Pharm 2010, 7:1816-1826.
13. Lee E.S., Na K., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett 2005, 5:325-329.
14. Toriyabe N., Hayashi Y., Harashima H. The transfection activity of R8-modified nanoparticles and siRNA condensation using pH sensitive stearylated-octahistidine. Biomaterials 2013, 34:1337-1343.
15. Wu H., Zhu L., Torchilin V.P. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials 2013, 34:1213-1222.
16. Zhao B.X., Zhao Y., Huang Y., Luo L.M., Song P., Wang X., et al. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials 2012, 33:2508-2520.
17. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33:9246-9258.
18. Tu Z., Volk M., Shah K., Clerkin K., Liang J.F. Constructing bioactive peptides with pH-dependent activities. Peptides 2009, 30:1523-1528.
19. Makovitzki A., Fink A., Shai Y. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res 2009, 69:3458-3463.
20. Midoux P., Kichler A., Boutin V., Maurizot J.C., Monsigny M. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug Chem 1998, 9:260-267.
21. Li L., He J., Eckert R., Yarbrough D., Lux R., Anderson M., et al. Design and characterization of an acid-activated antimicrobial peptide. Chem Biol Drug Des 2010, 75:127-132.
22. Zhang W., Song J., Zhang B., Liu L., Wang K., Wang R. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells. Bioconjug Chem 2011, 22:1410-1415.
23. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. JControl Release 2004, 100:41-52.
24. Yang T., Choi M.K., Cui F.D., Kim J.S., Chung S.J., Shim C.K., et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. JControl Release 2007, 120:169-177.
25. Nam H.Y., Kwon S.M., Chung H., Lee S.Y., Kwon S.H., Jeon H., et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. JControl Release 2009, 135:259-267.
26. Tamaru M., Akita H., Fujiwara T., Kajimoto K., Harashima H. Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. Biochem Biophys Res Commun 2010, 394:587-592.
27. Xiao K., Li Y., Luo J., Lee J.S., Xiao W., Gonik A.M., et al. The effect of surface charge on invivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011, 32:3435-3446.
28. Song J., Kai M., Zhang W., Zhang J., Liu L., Zhang B., et al. Cellular uptake of transportan 10 and its analogs in live cells: selectivity and structure-activity relationship studies. Peptides 2011, 32:1934-1941.
29. Strömstedt A.A., Ringstad L., Schmidtchen A., Malmsten M. Interaction between amphiphilic peptides and phospholipid membranes. Curr Opin Colloid 2010, 15:467-478.
30. Un K., Sakai-Kato K., Oshima Y., Kawanishi T., Okuda H. Intracellular trafficking mechanism, from intracellular uptake to extracellular efflux, for phospholipid/cholesterol liposomes. Biomaterials 2012, 33:8131-8141.
31. Adler A.F., Leong K.W. Emerging links between surface nanotechnology and endocytosis: impact on nonviral gene delivery. Nano Today 2010, 5:553-569.
32. Mudhakir D., Akita H., Tan E., Harashima H. Anovel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway. JControl Release 2008, 125:164-173.
33. Yandek L.E., Pokorny A., Floren A., Kneolke K., Langel U., Almeida P.F. Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers. Biophys J 2007, 92:2434-2444.
34. Xiang S., Tong H., Shi Q., Fernandes J.C., Jin T., Dai K., et al. Uptake mechanisms of non-viral gene delivery. JControl Release 2012, 158:371-378.
35. Bárány-Wallje E., Gaur J., Lundberg P., Langel U., Gräslund A. Differential membrane perturbation caused by the cell penetrating peptide Tp10 depending on attached cargo. FEBS Lett 2007, 581:2389-2393.
36. Chernenko T., Sawant R.R., Miljkovic M., Quintero L., Diem M., Torchilin V. Raman microscopy for noninvasive imaging of pharmaceutical nanocarriers: intracellular distribution of cationic liposomes of different composition. Mol Pharm 2012, 9:930-936.
37. Webb B.A., Chimenti M., Jacobson M.P., Barber D.L. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011, 11:671-677.
38. Wang J., Wang Y., Liang W. Delivery of drugs to cell membranes by encapsulation in PEG-PE micelles. JControl Release 2012, 160:637-651.
39. Yao H.J., Ju R.J., Wang X.X., Zhang Y., Li R.J., Yu Y., et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011, 32:3285-3302.
40. Huang J.G., Leshuk T., Gu F.X. Emerging nanomaterials for targeting subcellular organelles. Nano Today 2011, 6:478-492.
41. Mehta G., Hsiao A.Y., Ingram M., Luker G.D., Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. JControl Release 2012, 164:192-204.
42. Yao J., Zhang L., Zhou J., Liu H., Zhang Q. Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and paclitaxel based on hyaluronic acid-based multifunctional nanocarrier. Mol Pharm 2013, 10:1080-1091.
43. Yoshizawa Y., Kono Y., Ogawara K., Kimura T., Higaki K. PEG liposomalization of paclitaxel improved its invivo disposition andanti-tumor efficacy. Int J Pharm 2011, 412:132-141.
44. Qin Y., Chen H., Yuan W., Kuai R., Zhang Q., Xie F., et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 2011, 419:85-95.
45. Kuai R., Yuan W., Li W., Qin Y., Tang J., Yuan M., et al. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) co-modified liposomal delivery system via systemic administration. Mol Pharm 2011, 8:2151-2161.
46. Jain K., Kesharwani P., Gupta U., Jain N.K. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010, 394:122-142.
47. ®-the first FDA-approved nano-drug: lessons learned. JControl Release 2012, 160:117-134.
48. Hamano N., Negishi Y., Omata D., Takahashi T., Manandhar M., Suzuki R., et al. Bubble liposomes and ultrasound enhance the antitumor effects of AG73 liposomes encapsulating antitumor agents. Mol Pharm 2013, 10:774-779.
49. Wang Z., Yu Y., Dai W., Lu J., Cui J., Wu H., et al. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials 2012, 33:8451-8460.
50. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
51. Manzoor A.A., Lindner L.H., Landon C.D., Park J.Y., Simnick A.J., Dreher M.R., et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012, 72:5566-5575.
52. Huang Y., Jiang Y., Wang H., Wang J., Shin M.C., Byun Y., et al. Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev 2013, 3.http://dx.doi.org/10.1016/j.addr.2012.11.007.